GSK plc
GLAXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.
Other share classesGSK
Q3 2024 vs. Q2 2024
How the institutions holding GSK plc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 2 | 2 | 0 |
| Shares | 3.53M | 3.45M | −75.5K (−2.1%) |
| Value | $68.3M | $70.3M | +$2.00M (+2.9%) |
New holders (1)
Institutions that held GSK plc at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Eagle Bay Advisors LLC | 3,060 | $62.2K | 0.02% |
Sold out (1)
Institutions that held GSK plc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Kennedy Capital Management, Inc. | 163,308 | $3.16M |